ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.

RARE Ultragenyx Pharmaceutical Inc

39.05
-4.07 (-9.44%)
15 Jun 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
Ultragenyx Pharmaceutical Inc NASDAQ:RARE NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -4.07 -9.44% 39.05 38.00 39.55 41.00 38.16 40.93 4,107,675 01:00:00

Ultragenyx to Host Conference Call for Fourth Quarter and Full-Year 2023 Financial Results and Corporate Update

08/02/2024 9:00pm

GlobeNewswire Inc.


Ultragenyx Pharmaceutical (NASDAQ:RARE)
Historical Stock Chart


From Dec 2023 to Jun 2024

Click Here for more Ultragenyx Pharmaceutical Charts.

Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultrarare genetic diseases, today announced that it will host a conference call at 5:00 p.m. ET on Thursday, February 15, 2024, to discuss its financial results and corporate update for the fourth quarter and the year ending December 31, 2023.

The live and replayed webcast of the call will be available through the company’s website at https://ir.ultragenyx.com/events-presentations. To participate in the live call, please register by clicking on the following link (registration link) and you will be provided with dial-in details. The replay of the call will be available for 3 months.

About Ultragenyx Pharmaceutical Inc.Ultragenyx is a biopharmaceutical company committed to bringing novel products to patients for the treatment of serious rare and ultrarare genetic diseases. The company has built a diverse portfolio of approved therapies and product candidates aimed at addressing diseases with high unmet medical need and clear biology for treatment, for which there are typically no approved therapies treating the underlying disease.

The company is led by a management team experienced in the development and commercialization of rare disease therapeutics. Ultragenyx’s strategy is predicated upon time- and cost-efficient drug development, with the goal of delivering safe and effective therapies to patients with the utmost urgency.

For more information on Ultragenyx, please visit the company's website at: www.ultragenyx.com.

Contact Ultragenyx

InvestorsJoshua Higa(415) 475-6370

MediaCarolyn Wang(415) 225-5050

1 Year Ultragenyx Pharmaceutical Chart

1 Year Ultragenyx Pharmaceutical Chart

1 Month Ultragenyx Pharmaceutical Chart

1 Month Ultragenyx Pharmaceutical Chart

Your Recent History

Delayed Upgrade Clock